Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25:2755–63.PubMedCrossRefGoogle Scholar
Penel N, Bui BN, Bay J-O, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26:5269–74.PubMedCrossRefGoogle Scholar
Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model. J Clin Oncol. 2009;27:3148–53.PubMedCrossRefGoogle Scholar
Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28:1772–1779. Analysis of patients with advanced dermatofibrosarcoma protuberans treated with imatinib suggesting that a dose of 400 mg daily is as effective and better tolerated than 400 mg twice daily.
Cassier PA, Gelderblom H, Stacchiotti S, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 2012;118:1649–1655. Series documenting activity of imatinib in managing patients with recurrent or unresectable diffuse-type tenosynovial giant cell tumor.
Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133–40.PubMedCrossRefGoogle Scholar
Pacey S, Ratain M, Flaherty K, et al. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Investigational New Drugs. 2011;29:481–8.PubMedCrossRefGoogle Scholar
Ray-Coquard I, Italiano A, Bompas E, et al. Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist 2012;17(2):260–6.
von Mehren M, Rankin C, Goldblum JR, et al. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer. 2012;118:770–6.CrossRefGoogle Scholar
Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23:508–16.PubMedCrossRefGoogle Scholar
Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15:4220–7.PubMedCrossRefGoogle Scholar
Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol. 2009;27:3126–3132. Pazopanib was well-tolerated and had clinical activity in patients with advanced leiomyosarcomas, synovial sarcomas, and other STS types, but not adipocytic sarcomas.
Van Der Graaf WT, Blay J, Chawla SP, et al. PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—An EORTC STBSG Global Network Study (EORTC 62072). Abstract presented at the 47th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; June 3–7, 2011. Abstract LBA10002. The PALETTE study showed that pazopanib significantly improved PFS (median: 20 vs 7 weeks; HR = 0.31, 95 % CI 0.24-0.40 ; P < 0.0001).
George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27:3154–60.PubMedCrossRefGoogle Scholar
Stacchiotti S, Negri T, Zaffaroni N, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol. 2011;22:1682–1690. One of the first trials to demonstrate a significant objective response rate in alveolar soft part sarcoma treated with a drug.
Ghose A, Tariq Z, Veltri S. Treatment of multidrug resistant advanced alveolar soft part sarcoma with sunitinib. Am J Ther. 2012;19:e56–8.PubMedCrossRefGoogle Scholar
NCCN Guidelines, version 1. Soft Tissue Sarcoma. 2012. Available at: http://www.nccn.org/index.asp
. Accessed March 18, 2012.
Gardner K, Judson I, Leahy M, et al. Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. Abstract presented at the 45th Annual Meeting of the American Society of Clinical Oncology. Orlando, FL; May 29–June 2, 2009. Abstract 10523.
Kummar S, Strassberger A, Monks A, et al. An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS). Abstract presented at the 47th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; June 3–7, 2011. Abstract 10001.
US National Institutes of Health Clinical Trials: Sunitinib or cediranib for alveolar soft part sarcoma. 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT01391962
. Accessed March 3, 2012.
Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008;26:361–7.PubMedCrossRefGoogle Scholar
Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012, 30:78–84. In this relatively large study of patients with unresectable or metastatic sarcoma, 29 % had stable disease or partial response at 16 weeks, but the objective response rate was less than 5 %.
Chawla SP, Blay J, Ray-Coquard IL, et al. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). Abstract presented at the 47th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; June 3–7, 2011. Abstract 10005.
Okuno S, Bailey H, Mahoney MR, et al. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcoas. Cancer. 2011;117:3468–75.PubMedCrossRefGoogle Scholar
Italiano A, Kind Ml, Stoeckle E, Jones N, Coindre J-M, Bui B. Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway. Anticancer Drugs. 2011;22:463–467.
Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011;17:871–9.PubMedCrossRefGoogle Scholar
Bullock K, Petros W, Younis I, et al. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemother Pharmacol. 2011;67:465–74.PubMedCrossRefGoogle Scholar
Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010;28:835–840. Small series demonstrating that malignant PEComa may respond to treatment with mTOR inhibitor.
Italiano A, Delcambre C, Hostein I, et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol. 2010;21:1135–7.PubMedCrossRefGoogle Scholar
Dabora SL, Franz DN, Ashwal S, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS One. 2011;6:e23379.PubMedCrossRefGoogle Scholar
Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17:4071–81.PubMedCrossRefGoogle Scholar
Wolff N, Kabbani W, Bradley T, Raj G, Watumull L, Brugarolas J. Sirolimus and temsirolimus for epithelioid angiomyolipoma. J Clin Oncol. 2010;28:e65–8.PubMedCrossRefGoogle Scholar
Shitara K, Yatabe Y, Mizota A, Sano T, Nimura Y, Muro K. Dramatic tumor response to everolimus for malignant epithelioid angiomyolipoma. Jpn J Clin Oncol. 2011;41:814–6.PubMedCrossRefGoogle Scholar
McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364:1595–606.PubMedCrossRefGoogle Scholar
Stacchiotti S, Palassini E, Sanfilippo R, et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol. 2012;23(2):501–8.
Mir O, Domont J, Cioffi A, et al. Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. Eur J Cancer. 2011;47:515–9.PubMedCrossRefGoogle Scholar
West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA. 2006;103:690–5.PubMedCrossRefGoogle Scholar
Blay J-Y, El Sayadi H, Thiesse P, Garret J, Ray-Coquard I. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol. 2008;19:821–2.PubMedCrossRefGoogle Scholar
Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol. 2011;22:452–7.PubMedCrossRefGoogle Scholar
Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010;16:4884–91.PubMedCrossRefGoogle Scholar
Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res. 2011;17:4082–90.PubMedCrossRefGoogle Scholar
Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363:1727–1733. This case report of two patients led to the recent update to the NCCN guidelines to include crizotinib as an option for management of patients with ALK + IMT.
Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. The Lancet Oncology 2010;11:275–280. Phase II study demonstrating significant activity of denosumab, a monoclonal antibody to RANK ligand, in the management of patients with locally advanced or metastatic giant cell tumor of bone.